EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSOMYG00000023504
Gene Symbol: KCND3
1 Cross references
186 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSOMYG00000005998
Gene Symbol: KCNQ3
1 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSOMYG00000017151
Gene Symbol: KCNQ5
1 Cross references
190 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSOMYG00000039878
Gene Symbol: KCNQ5
1 Cross references
190 Possible Orthologues:

Potassium Voltage-Gated Channel, Shal-Related Subfamily, Member 3

Ensembl ID : ENSOMYG00000054558
Gene Symbol: KCND3
1 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2a

Ensembl ID : ENSOMYG00000029886
Gene Symbol: KCNH2A
1 Cross references
151 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2a

Ensembl ID : ENSOMYG00000037962
Gene Symbol: KCNH2A
1 Cross references
150 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSOMYG00000057689
Gene Symbol: PSEN1
1 Cross references
195 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSOMYG00000026474
Gene Symbol: PSEN2
2 Cross references
200 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSOMYG00000037566
Gene Symbol: PGR
1 Cross references
193 Possible Orthologues:

Prostaglandin E Receptor 1a (Subtype Ep1)

Ensembl ID : ENSOMYG00000013344
Gene Symbol: PTGER1A
1 Cross references
162 Possible Orthologues:

Prostaglandin E Receptor 1a (Subtype Ep1)

Ensembl ID : ENSOMYG00000054043
Gene Symbol: PTGER1A
1 Cross references
161 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).